journal article·2022-07

Thermodynamic and kinetic mechanism of phase transformation of levofloxacin hydrochloride

Han Liu, Xiunan Zhang, Ting Wang, Xin Huang, Kui Chen, Na Wang, Shanshan Yu, Yuyuan Dong, Hongxun Hao

Particuology· Volume 66
Publisher page

Abstract

Abstract In this work, thermodynamic and kinetic factors that affect formation and phase transformation process of different solid forms of levofloxacin hydrochloride were investigated in detail. Dynamic vapor sorption experiments (DVS) and varying temperature-powder X-ray diffraction (VT-PXRD) experiments were carried out to study moisture-dependent stability, thermal stability as well as the transformation process between Form I and Form II. Critical water activities of levofloxacin hydrochloride were determined in temperature range of 5.0–45.0 °C. Raman spectroscopy was applied to in situ monitor the temperature-induced phase transformation and the hydration process of levofloxacin hydrochloride, and one possible mechanism consisting of multiple chemical equilibria was proposed to analyze the effect of thermodynamic and kinetic factors on the formation and transformation of different solid forms. Results show that the anhydrate, Form II would transform to the monohydrate, Form I more easily with the increasing water content. And the transition point moves toward higher water contents as the temperature increases. The results suggested that, except for thermodynamic factors, kinetic factors also play an essential role in controlling the solid forms of polymorphic compounds.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Crystallization and Solubility Studies · Drug Solubulity and Delivery Systems · Crystallography and molecular interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (42)

Show source-provided references
1. Hyphenated spectroscopy as a polymorph screening tool10.1016/j.jpba.2007.02.009 ↗
2. A solid-state dehydration process associated with a significant change in the topology of dihydrogen phosphate chains, established from powder X-ray diffraction10.1021/cg800226e ↗
3. Detailed analysis of packing efficiency allows rationalization of solvate formation propensity for selected structurally similar organic molecules10.1021/acs.cgd.7b01457 ↗
4. On the formation and transformations of organic salt hydrates: Four encenicline hydrochloride monohydrates and respective isostructural desolvates10.1021/acs.cgd.7b01561 ↗
5. Inconvenient truths about solid form landscapes revealed in the polymorphs and hydrates of gandotinib10.1021/acs.cgd.9b00162 ↗
6. Mesophase-mediated crystallization of poly(butylene-2,6-naphthalate): An example of Ostwald’s rule of stages10.1021/mz300349z ↗
7. Reversible crystal phase change between guanosine dihydrate and anhydrous guanosine by a heating–cooling process10.1021/acs.cgd.9b01404 ↗
8. Solid forms selection of spironolactone: Ternary phase diagram and nucleation process10.1021/acs.iecr.9b06153 ↗
9. The effect of temperature and solvent composition on transformation of β- to α-glycine as monitored in situ by FBRM and PVM10.1021/op900134w ↗
10. Understanding the role of water in different solid forms of avibactam sodium and its affecting mechanism10.1021/acs.cgd.9b01459 ↗
11. Factors affecting crystallization of hydrates10.1111/j.2042-7158.2010.01186.x ↗
12. Polymorph screening: Influence of solvents on the rate of solvent-mediated polymorphic transformation10.1002/jps.1137 ↗
13. Editorial: Crystallization for pharmaceutical and food science
14. Polymorphism and drug availability. Solubility relationships in the methylprednisolone system10.1002/jps.2600520210 ↗
15. Hu · 2015
16. Organic crystal hydrates: What are the important factors for formation10.1039/B612529H ↗
17. Phase transitions of antibiotic clarithromycin forms I, IV and new form VII crystals10.1016/j.ijpharm.2018.05.073 ↗
18. Pseudopolymorphs of LB30870, a direct thrombin inhibitor: One dimensional solvent channel structures explain reversible hydration/dehydration10.1021/acs.cgd.7b00927 ↗
19. Analysis of storage environmental factors of solid dosage form drugs
20. Process design for anti-solvent crystallization of erythromycin ethylsuccinate in oiling-out system10.1021/acs.iecr.6b00795 ↗
21. Insights into polymorphic transformation of l-glutamic acid: A combined experimental and simulation study10.1021/cg501833u ↗
22. Solubility and thermodynamic mixing and dissolution properties of empagliflozin in pure and binary solvent systems10.1016/j.molliq.2020.113004 ↗
23. Examining solution and solid state composition for the solution-mediated polymorphic transformation of carbamazepine and piracetam10.1021/cg201665z ↗
24. Studies on the formation and transformation of solid phases. Supersaturation and practicing cooling
25. Thermodynamic and kinetic studies on the polymorphic transformations of puerarin hydrates10.1016/j.ijpharm.2021.120374 ↗
26. Estimating thermodynamic stability relationship of polymorphs of sofosbuvir10.1021/acs.cgd.5b01038 ↗
27. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph
28. The impact of operating parameters on the polymorphic transformation of d-mannitol characterized in situ with Raman spectroscopy, FBRM, and PVM10.1021/op100228f ↗
29. Effect of temperature and solvent of solvent-mediated polymorph transformation on ASP3026 polymorphs and scale-up10.1021/acs.oprd.6b00068 ↗
30. Mechanistic insight into the evaporative crystallization of two polymorphs of nitrofurantoin monohydrate10.1016/j.jcrysgro.2009.02.004 ↗
31. Determination and correlation of solubility and solution thermodynamics of ethenzamide in different pure solvents10.1016/j.fluid.2016.08.019 ↗
32. The role of solvent composition and polymorph surface chemistry in the solution-mediated phase transformation process of cefaclor10.1021/acs.iecr.8b04462 ↗
33. Investigation of solution-mediated phase transformation of cefuroxime acid to its acetonitrile solvate10.1021/op500304u ↗
34. Solution-mediated phase transformation of argatroban: Ternary phase diagram, rate-determining step, and transformation kinetics10.1021/acs.iecr.6b04760 ↗
35. Nucleation, growth, and solvated behavior of erythromycin as monitored in situ by using FBRM and PVM10.1021/op0600097 ↗
36. Hydrates and solvates of acotiamide hydrochloride: Crystallization, structure, stability, and solubility10.1021/acs.cgd.8b01360 ↗
37. Effects of hydrogen bond acceptor ability of solvents on molecular self-assembly of sulfadiazine solvates10.1016/j.xphs.2018.06.026 ↗
38. Phase transformation between Anhydrate and monohydrate of sodium dehydroacetate10.1021/ie504873p ↗
39. The mechanism of solvent-mediated desolvation transformation of lenvatinib mesylate from dimethyl sulfoxide solvate to form D10.1107/S2052520620003935 ↗
40. Crystal structure, thermal crystal form transformation, desolvation process and desolvation kinetics of two novel solvates of ciclesonide10.1039/C6RA08351J ↗
41. Polymorphs and hydrates of apatinib mesylate: Insight into the crystal structures, properties and phase transfomations10.1021/acs.cgd.6b01230 ↗
42. Thermodynamic and population balance models for solvent-mediated phase transformation of lansoprazole10.1016/j.ces.2019.06.020 ↗